Arrowstreet Capital Limited Partnership Sells 8,594 Shares of Amedisys, Inc. (NASDAQ:AMED)

Arrowstreet Capital Limited Partnership reduced its position in Amedisys, Inc. (NASDAQ:AMED) by 63.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,976 shares of the health services provider’s stock after selling 8,594 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Amedisys were worth $452,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. ABC Arbitrage SA purchased a new stake in Amedisys during the fourth quarter valued at approximately $2,522,000. Geode Capital Management LLC lifted its holdings in shares of Amedisys by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock valued at $54,746,000 after purchasing an additional 7,071 shares during the last quarter. Oddo BHF Asset Management Sas acquired a new stake in shares of Amedisys in the 3rd quarter worth $7,238,000. Empowered Funds LLC purchased a new position in Amedisys during the 4th quarter worth $318,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Amedisys during the 4th quarter valued at about $590,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Price Performance

Shares of AMED opened at $91.51 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The company’s fifty day moving average price is $92.20 and its 200-day moving average price is $92.01. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95. The firm has a market capitalization of $3.00 billion, a PE ratio of 36.31, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The firm had revenue of $598.05 million for the quarter, compared to analysts’ expectations of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. On average, equities research analysts predict that Amedisys, Inc. will post 4.4 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Stephens reissued an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Amedisys presently has an average rating of “Hold” and an average price target of $101.00.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.